Oral Care Heavyweights Disagree On Plaque Claim Support, Stannous Fluoride
This article was originally published in The Rose Sheet
Executive Summary
Procter & Gamble and Pfizer take opposing views on the way therapeutic standalone antiplaque claims should be regulated in comments submitted to FDA Feb. 20
You may also be interested in...
Oral Care Ingredient Dosage Form Flexibility Urged By P&G, Pfizer
Category I active ingredient dosage forms other than those reviewed by the Dental Plaque Subcommittee should be allowed in the antiplaque/antigingivitis final monograph, according to Pfizer
Oral Care Ingredient Dosage Form Flexibility Urged By P&G, Pfizer
Category I active ingredient dosage forms other than those reviewed by the Dental Plaque Subcommittee should be allowed in the antiplaque/antigingivitis final monograph, according to Pfizer
Triclosan Antigingivitis/Antiplaque Monograph Status Sought By Ciba
Ciba Specialty Chemicals requests that FDA include triclosan in its upcoming OTC monograph for antigingivitis/antiplaque oral care products in a recently-filed application